Session: Featured MPC Session: Development of a Novel Platform to Deliver Large Volume Synthetic Peptides: The Commercialization of Tirzepatide

Learn about the development and commercialization of Eli Lilly's GLP-1 pill. This special MPC session will feature an in-depth success story from Ely Lilly on their CMC development and commercialization of tirzepatide, a dual GIP/GLP1 receptor agonist approved for treatment of type 2 diabetes. Three speakers will describe the strategy, implementation, and the new manufacturing facility developed. This case study is expected to have broad appeal to ChE’s beyond the synthetic peptide space given the way the synthesis process and control strategies were developed, the new facility designed to execute the process, and the topical nature of these emerging peptide therapies.